Trial Profile

Phase 1 Trial of Gemcitabine Combined With the Elimusertib (BAY 1895344) ATR Inhibitor With Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 28 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elimusertib (Primary) ; Gemcitabine (Primary)
Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

22 May 2025 Planned End Date changed from 6 May 2026 to 20 May 2026.
08 May 2025 Planned End Date changed from 1 Feb 2025 to 6 May 2026.
13 Aug 2024 Planned End Date changed from 1 Jul 2024 to 1 Feb 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com